Association of clinical parameters and overall survival (OS) in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)

被引：0
|
作者：
Stenehjem, David D.
Parikh, Kinjal
Batten, Julia Anne
Van Atta, Joan
Crispin, Hilda
Sageser, Daniel S.
Grossmann, Kenneth F.
Wang, Junfeng
Tantravahi, Srinivas Kiran
Samlowski, Wolfram E.
Agarwal, Neeraj
机构：
[1] Univ Utah, Coll Pharm, Pharmacotherapy Outcomes Res Ctr, Salt Lake City, UT 84112 USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[3] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.476
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
476
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC)
    Garcia, J. A.
    Rini, B. I.
    Mekhail, T.
    Triozzi, P.
    Elson, P.
    Nemec, C.
    Bukowski, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] The application of high-dose interleukin-2 for metastatic renal cell carcinoma
    McDermott, David F.
    MEDICAL ONCOLOGY, 2009, 26 : 13 - 17
  • [23] High-dose interleukin-2 in metastatic renal cell carcinoma - Reply
    McDermott, DF
    Atkins, MB
    Regan, MM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6798 - 6799
  • [24] The application of high-dose interleukin-2 for metastatic renal cell carcinoma
    David F. McDermott
    Medical Oncology, 2009, 26 : 13 - 17
  • [25] First-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts)
    Ernstoff, M. S.
    Regan, M. M.
    McDermott, D. F.
    Sosman, J. A.
    Dutcher, J. P.
    Clark, J. I.
    Crocenzi, T. S.
    Ochoa, A.
    Atkins, M. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] The association of tumor infiltrating CD8+ and Foxp3 cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).
    Pignon, Jean-Christophe
    Jegede, Opeyemi
    Novak, Jesse
    Mahoney, Kathleen Margaret
    Mier, James Walter
    Freeman, Gordon J.
    Atkins, Michael B.
    Catalano, Paul J.
    Signoretti, Sabina
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
    Buchbinder, Elizabeth I.
    Gunturi, Anasuya
    Perritt, Jessica
    Dutcher, Janice
    Aung, Sandra
    Kaufman, Howard L.
    Ernstoff, Marc S.
    Miletello, Girald P.
    Curti, Brendan D.
    Daniels, Gregory A.
    Patel, Sapna P.
    Kirkwood, John M.
    Hallmeyer, Sigrun
    Clark, Joseph I.
    Gonzalez, Rene
    Richart, John M.
    Lutzky, Joe
    Morse, Michael A.
    Sullivan, Ryan J.
    McDermott, David F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [28] Potential impact of prior high-dose IL-2 on the outcomes of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC).
    Rosenbaum, Eli
    Gottfried, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Carducci, Michael Anthony
    Sinibaldi, Victoria J.
    Neiman, Victoria
    Sarid, David
    Gez, Eliahu
    Hayat, Henry
    Peer, Avivit
    Sella, Avishay
    Mermershtain, Wilmosh
    Rouvinov, Keren
    Berger, Raanan
    Kejzman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [29] The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma
    Hughes, Tasha
    Klairmont, Matthew
    Broucek, Joseph
    Iodice, Gail
    Basu, Sanjib
    Kaufman, Howard L.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (04) : 459 - 465
  • [30] A Pilot Study of Denileukin Diftitox (DD) in Combination With High-dose Interleukin-2 (IL-2) for Patients With Metastatic Renal Cell Carcinoma (RCC)
    Atchison, Elizabeth
    Eklund, John
    Martone, Brenda
    Wang, Lili
    Gidron, Adi
    Macvicar, Gary
    Rademaker, Alfred
    Goolsby, Charles
    Marszalek, Laura
    Kozlowski, James
    Smith, Norm
    Kuzel, Timothy M.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (07) : 716 - 722
12345